NTLA Investors are Reminded of the Final Opportunity to Lead Intellia Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

Core Viewpoint - A class action lawsuit has been filed against Intellia Therapeutics, Inc. for alleged violations of securities laws, specifically related to misleading statements about the development of its drug NTLA-3001 [1][4]. Group 1: Lawsuit Details - The lawsuit is based on claims that Intellia made false and misleading statements regarding its drug development and marketing strategies, particularly concerning NTLA-3001 [4]. - Investors who purchased Intellia's securities between July 30, 2024, and January 8, 2025, are encouraged to participate in the class action [2]. - The class has not yet been certified, meaning that potential class members are not currently represented by an attorney [3]. Group 2: Allegations Against the Company - The complaint alleges that Intellia provided investors with a false impression of having reliable information about NTLA-3001's development [4]. - It is claimed that the company's reports on timelines for future studies were unsustainable due to high costs and inefficient delivery methods [4]. - The company reportedly struggled to provide timely doses of NTLA-3001 and maintain adequate staffing levels, leading to materially misleading public statements [4].